BIO-PREDISC-TIA SWISS Cohort Study

Dr. med. Carlo Cereda64 enrolled

Overview

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cerebrovascular Disease, Ischemic Stroke

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting \<24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset. * At least 18 years old. * Having given their Informed Consent. Exclusion Criteria: * · Patients with ocular TIA (Amaurosis fugax). * Patients that still have neurological deficits at the moment of inclusion. * Contraindication to perform MRI. * For women: pregnancy.

Locations (2)

Centre hospitalier Vaudois

Lausanne, Canton of Vaud, Switzerland

Ospedale Regionale di Lugano

Lugano, Canton Ticino, Switzerland

Outcomes

Primary Outcomes

Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.

Diagnostic performance according to PREDISC scale

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.